Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

Trial Details

NCT ID

NCT07014917

Phase

PHASE2

Sponsor

Zulfa Omer

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Venetoclax
• Acalabrutinib

Locations (sample)

• Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

• Diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) as defined by the IWCLL including variation of flow cytometry, …
• a. Note: Variation in flow cytometry is defined as patients who have atypical immunophenotyping for CLL (CD5 negative, CD23 negative or surface exp…
• Men and Women ≥18 years of age.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 with no deterioration over the previous 2 weeks prior to baseline or day…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.